Joseph(Joe) Basile buys 6,406 Neuren Pharmaceuticals Limited (ASX:NEU) shares

Neuren Pharmaceuticals Limited (ASX:NEU – Get Free Report) insider Joseph(Joe) Basile bought 6,406 shares of the stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of $15.73 ($10.63) per share, for a total transaction of $100,766.38 ($68,085.39).

Joseph(Joe) Basile also recently traded:

• On Tuesday, June 11th, Joseph(Joe) Basile acquired 5,000 shares of Neuren Pharmaceuticals stock. The stock was bought at an average cost of $19.49 ($13.17) per share, for a total transaction of $97,450.00 ($65,844.59).

Neuren Pharmaceuticals price performance

About Neuren Pharmaceuticals

(Get a free report)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It is developing and commercializing DAYBUE (trophinetide), which has been registered to treat Rett syndrome in adults and children and adolescents aged 2 years and older, as well as in the Phase 2 clinical trial to treat fragile X syndrome.

Recommended articles

Receive daily news and reviews for Neuren Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com ‘s FREE daily email newsletter.